- Home
- OM vs CAPR Comparison
OM vs CAPR Comparison
Compare OM & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- CAPR
- Stock Information
- Founded
- OM 2003
- CAPR 2005
- Country
- OM United States
- CAPR United States
- Employees
- OM N/A
- CAPR N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OM Health Care
- CAPR Health Care
- Exchange
- OM Nasdaq
- CAPR Nasdaq
- Market Cap
- OM 220.8M
- CAPR 324.6M
- IPO Year
- OM 2020
- CAPR N/A
- Fundamental
- Price
- OM $13.91
- CAPR $6.28
- Analyst Decision
- OM Hold
- CAPR Strong Buy
- Analyst Count
- OM 1
- CAPR 8
- Target Price
- OM $22.00
- CAPR $24.75
- AVG Volume (30 Days)
- OM 288.8K
- CAPR 1.4M
- Earning Date
- OM 08-06-2025
- CAPR 08-11-2025
- Dividend Yield
- OM N/A
- CAPR N/A
- EPS Growth
- OM N/A
- CAPR N/A
- EPS
- OM N/A
- CAPR N/A
- Revenue
- OM $119,304,000.00
- CAPR $13,392,150.00
- Revenue This Year
- OM $12.37
- CAPR N/A
- Revenue Next Year
- OM $10.52
- CAPR $6,061.53
- P/E Ratio
- OM N/A
- CAPR N/A
- Revenue Growth
- OM 2.47
- CAPR N/A
- 52 Week Low
- OM $5.85
- CAPR $3.98
- 52 Week High
- OM $25.35
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- OM 43.41
- CAPR 36.33
- Support Level
- OM $13.60
- CAPR $6.17
- Resistance Level
- OM $14.35
- CAPR $7.30
- Average True Range (ATR)
- OM 0.60
- CAPR 0.43
- MACD
- OM 0.26
- CAPR -0.11
- Stochastic Oscillator
- OM 80.09
- CAPR 4.53
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.